Larimar Presents Nomlabofusp Data at Ataxia Congress
Larimar Therapeutics will present three poster presentations on nomlabofusp at the International Congress for Ataxia Research 2026 in Atlanta.
Updated on Nov. 5, 2026 in Biotech
Larimar Therapeutics announced that it will give three poster presentations on its drug nomlabofusp at the International Congress for Ataxia Research 2026, held November 10-13, 2026, in Atlanta, Georgia. The posters will cover previously disclosed interim clinical data from an ongoing open-label study and new plasma lipid and gene expression analyses in participants with Friedreich's ataxia.
Why it matters
The presentations will add new analyses to the clinical picture of nomlabofusp in people with Friedreich's ataxia, a rare neurodegenerative disease. Scientific conference presentations of this kind give the research community and patients a closer look at how the treatment is being studied.
The three posters cover interim observations from an open-label study of long-term daily nomlabofusp administration, along with plasma lipid profiles and dysregulated gene expression in treated Friedreich's ataxia patients. The results themselves have not been disclosed in the announcement, and no comparator data was provided.
The players
Larimar Therapeutics
A clinical-stage biotechnology company focused on complex rare diseases, headquartered in Bala Cynwyd, Pennsylvania, and trading on Nasdaq under the symbol LRMR.
The details
The posters will be presented during Poster Session Day 3 in the Poster and Exhibitor Hall (D) at the Cobb Convention Center in Atlanta. The presentations address interim observations, plasma lipid profiles, and gene expression changes in study participants with Friedreich's ataxia.
Timeline
November 10-13, 2026: International Congress for Ataxia Research 2026 held in Atlanta, Georgia.
November 12, 2026, 6:30-7:30 p.m. ET: Poster Session Day 3 featuring all three Larimar presentations.
Roadmap
The International Congress for Ataxia Research is the field's annual forum where ataxia researchers share clinical and mechanistic findings. Larimar's posters place nomlabofusp's interim data and biomarker analyses alongside other ataxia programs at that forum.
For patients and families affected by Friedreich's ataxia, the posters offer a look at how nomlabofusp is being studied over the long term, including interim observations from daily dosing. The presentations do not, however, establish any change to how the drug is accessed or prescribed.
The takeaway
Readers following Friedreich's ataxia research can watch for the November 2026 poster data as a source of new detail on nomlabofusp's effects. The announcement itself contains no results, so the substance of the findings will only be clear once the posters are presented.
What happens next
The three poster presentations will be given during Poster Session Day 3 on November 12, 2026, from 6:30 to 7:30 p.m. ET at the Cobb Convention Center in Atlanta.
Further reading
For more on drug development in this field, see Biotech.
More information
Visit the Larimar Therapeutics company website for more information about nomlabofusp and the company.
Source note: This article includes information reported by The Manila times.
